Actuate Therapeutics, Inc.
corporate_fare Company Profile
Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ACTU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ACTU spans 10-Q, 8-K, 424B5, S-1/A.
Recent high-impact activity:
- Actuate Beats on Q3 Loss Per Share but Cash Falls to $2.1M With Going-Concern Doubt
- Actuate Q3 10-Q: $2.1M Cash, Going-Concern Doubt, Over-Allotment Adds $1.5M
- Actuate Gets Nasdaq Bid-Price Notice, 180 Days to Reach $1.00
- Actuate Closes $11.0M Offering, Nets $9.96M With 46.5M Dilutive Shares and Warrants
- Actuate Finalizes $11.0M Offering: 30.99M Shares Plus 15.49M Warrants at $0.71
Financial Snapshot
Short Interest & Short Volume
2.12 days to coverFINRA reported short interest of 1,298,553 shares in ACTU as of the October 30, 2026 settlement, a 30.5% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 44.4% of ACTU volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for ACTU, detected from its recent SEC filings · based on capital-structure filings through 2026-10-28.
Offering Priced at $0.71 Per Two Shares · Net Proceeds of $9.96 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →